https://www.globenewswire.com/news-release/2025/02/27/3033688/0/en/Verve-Therapeutics-Announces-Pipeline-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
Verve Therapeutics Announces Pipeline Progress and Reports
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data...
verve therapeuticsannouncespipelineprogressreports
https://www.fool.com/investing/2023/11/16/verve-therapeutics-why-great-results-arent-enough/
Verve Therapeutics: Why Great Results Aren't Enough | The Motley Fool
Nov 16, 2023 - The company's twist on CRISPR appears to work as intended but that didn't stop this biotech's stock price from collapsing.
verve therapeuticsgreat results
https://www.prnewswire.com/news-releases/verve-therapeutics-inc-class-action-the-gross-law-firm-reminds-verve-therapeutics-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-28-2024--verv-302278364.html
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of...
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares...
the gross lawverve therapeuticsclass action
https://www.fool.com/investing/2022/11/07/why-verve-therapeutics-stock-dropped-2633-on-monda/
Why Verve Therapeutics' Stock Dropped 26.33% on Monday | The Motley Fool
Nov 7, 2022 - A trial for the company's lead therapy was put on hold.
verve therapeutics
https://www.fiercebiotech.com/keyword/verve-therapeutics
Verve Therapeutics | Fierce Biotech
verve therapeuticsfiercebiotech
https://www.prnewswire.com/news-releases/verv-investors-have-opportunity-to-lead-verve-therapeutics-inc-securities-fraud-lawsuit-filed-by-the-schall-law-firm-302281393.html
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by...
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics,...
https://www.fool.com/investing/2025/06/20/why-lillys-bid-for-verve-therapeutics-sent-the-sto/
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week | The Motley Fool
Jun 20, 2025 - Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
https://www.prnewswire.com/news-releases/verv-deadline-verv-investors-have-opportunity-to-lead-verve-therapeutics-inc-securities-fraud-lawsuit-302281103.html
VERV Deadline: VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud...
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August...
https://www.businesswire.com/news/home/20210119005273/en/Verve-Therapeutics-Secures-%2494-Million-in-Series-B-Financing-to-Advance-Pipeline-of-Gene-Editing-Medicines-for-Cardiovascular-Disease
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing...
Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 m...